A Phase II Study of Deferasirox in Patients With Red Blood Cell Transfusion Dependent Myelodysplastic Syndromes
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Deferasirox (Primary)
- Indications Anaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 20 Mar 2017 Planned primary completion date changed from 1 Mar 2019 to 2 Mar 2020.
- 20 Mar 2017 Status changed from not yet recruiting to recruiting.
- 27 Oct 2016 New trial record